• Mike Adelstein
  • March 23, 2021

Microneedles for vaccine delivery

Microneedles for vaccine delivery

Microneedle-based drug delivery has the potential to be a transformative technology for the delivery of biologics and vaccines. It may provide enhanced therapeutic profiles for therapeutics and vaccines. It allows for the administration of lower levels of drugs to achieve the same therapeutic endpoints. Additionally, microneedles provide an alternative to traditional hypodermic needles. This industry provides a means to overcome one of the biggest barriers to patient compliance and safety for the treatment of chronic diseases and routine vaccination. The variation in the microneedle types could also prove useful in controlling the kinetics of vaccine release. The importance of overcoming stratum corneum barrier is central to the efficient Microneedle-mediate transdermal and intradermal delivery. 1,2

Several new transdermal products mediated by microneedle methods have already been marketed and a few others reach their late-stage development. According to “The Microneedles for Transdermal and Intradermal Drug Delivery, 2014-2030” report, more than 70% of the products in development are patches incorporating solid or dissolvable needles, the rest are hollow microneedle arrays that employ the use of a syringe. However, microneedle technologies have not reached their full maturity, yet due to a lack of cost-effective manufacturing technologies. With several new microneedle-based therapeutic product launches by the end of this decade, the report concludes that the overall market for microneedle-based delivery devices will reach annual sales of 485 million units by 2030. https://www.medicaldesignandoutsourcing.com/microneedle-patches-enable-superior-drug-delivery

The images shown here are microneedle molds (diameters of 250 µm to 1 mm) prepared using Potomac’s precision laser etching technologies.

References:

  1. Tuan-Mahmood, T.-M. et al. Microneedles for intradermal and transdermal drug delivery. Eur. J. Pharm. Sci. 50, 623–37 (2013).
  2. Rouphael, N. G. et al. The safety, immunogenicity, and acceptability of inactivated influenza vaccine delivered by microneedle patch (TIV-MNP 2015): a randomised, partly blinded, placebo-controlled, phase 1 trial. Lancet 390, 649–658 (2017).

 

 

Other Posts

Did Theranos Prove Lab On a Chip is Not a Viable Technology?

Theranos has been a nightmare for legitimate medical diagnostics researchers and startups because Lab On a Chip technology was at the center of the failed blood testing startup.  Once Silicon Valley and Wall Street darlings, Theranos made headlines not just because the company was forced to shut down but because founder Elizabeth Holmes was convicted…

  • Mike Adelstein
  • January 18, 2022

2021: A Year of Potomac Manufacturing Innovations

After 2020, the year of pivoting to meet emergency Covid-19 PPE manufacturing requirements, 2021 has proven to be a year when Potomac expanded innovation in order to meet ever more demanding customer challenges in a variety of industries. Although cool, new concepts in the medical device, microfluidics, micro-electronics, aerospace, or consumer industries may grab all…

  • Potomac Photonics
  • December 28, 2021

Potomac Innovation Report

            Breaking Down Barriers for a Biotech Startup There are many barriers to market entry for new biotech products, most of which start with demonstrating the feasibility of a new technology.  However, once proof of concept is established in the prototyping stage, getting a product to market requires overcoming big hurdles in high volume manufacturing.  Startups…

  • Potomac Photonics
  • December 1, 2021